首页> 外国专利> Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof

Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof

机译:针对血管生成素-1和血管生成素-2的抗体及其用途

摘要

Isolated monoclonal antibody comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain comprises 3 CDR and said light chain comprises 3 CDR, wherein the sequences of said CDRs of said antibody are selected from the group consisting of: (a) SEQ ID NO: 18, 26, 32 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (b) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (c) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 20, 27, 36 of the LC, (d) SEQ ID NO: 18 , 26, 37 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (e) SEQ ID NO: 18, 26, 38 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (f) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (g) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 21 , 27, 33 of the LC, (h) SEQ ID NO: 18, 28, 39 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (i) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 22, 27, 33 of the LC, (j) SEQ ID NO: 18, 26, 32 of the HC plus SEQ I D NO: 22, 27, 33 of the LC, (k) SEQ ID NO: 18, 29, 39 of the HC plus SEQ ID NO: 19, 27, 33 of the LC, (l) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 23, 27, 33 of the LC, (m) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 20, 27.40 of the LC, ( n) SEQ ID NO: 18, 26, 32 of the HC plus SEQ ID NO: 21, 27, 33 of the LC, (o) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 24, 27, 33 of the LC, (p) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 21, 27, 33 of the LC, (q) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 23, 27, 33 of the LC, (r) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 20, 30, 33 of the LC, (s) SEQ ID NO : 18, 26, 34 of the HC plus SEQ ID NO: 25, 27, 33 of the LC, (t) SEQ ID NO: 18, 26, 35 of the HC plus SEQ ID NO: 20, 30, 33 of the LC, (u) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 20, 27, 40 of the LC, and (v) SEQ ID NO: 18, 26, 34 of the HC plus SEQ ID NO: 20, 31, 33 of the LC; wherein said antibody specifically binds to at least one of the Ang1 and Ang2 ligands of the Tie 2 receptor.
机译:分离的单克隆抗体,其包含重链可变域和轻链可变域,其中所述重链包含3个CDR,并且所述轻链包含3个CDR,其中所述抗体的所述CDR的序列选自:(a) )HC的SEQ ID NO:18、26、32加上LC的SEQ ID NO:19、27、33,(b)HC的SEQ ID NO:18、26、34加上LC的SEQ ID NO:19,27 LC的SEQ ID NO:18、26、35加上LC的SEQ ID NO:20、27、36(d)HC的SEQ ID NO:18、26、37加上LC的SEQ ID NO:19、27、33,(e)HC的SEQ ID NO:18、26、38,加上LC的SEQ ID NO:19、27、33,(f)SEQ ID NO: HC的18、26、35加上LC的SEQ ID NO:19、27、33(g)HC的SEQ ID NO:18、26、34加上LC的SEQ ID NO:21、27、33 (h)HC的SEQ ID NO:18、28、39和LC的SEQ ID NO:19、27、33,(i)HC的SEQ ID NO:18,26,34加上SEQ ID NO: LC的22、27、33,(j)HC的SEQ ID NO:18、26、32加上SEQ ID NO: LC的22、27、33,HC的(k)SEQ ID NO:18、29、39以及LC的SEQ ID NO:19、27、33,(l)SEQ ID NO:18、26、34 HC加上LC的SEQ ID NO:23、27、33的(m)HC加上LC的SEQ ID NO:20、27.40的SEQ ID NO:18、26、35,(n)SEQ ID NO :HC的18、26、32加上LC的SEQ ID NO:21、27、33,(o)HC的SEQ ID NO:18、26、35加上LC的SEQ ID NO:24、27、33 LC,(p)HC的SEQ ID NO:18、26、35加LC的SEQ ID NO:21、27、33,(q)HC的SEQ ID NO:18、26、35加SEQ ID NO: :LC的23、27、33,(r)HC的SEQ ID NO:18、26、34,以及LC的SEQ ID NO:20、30、33,(s)SEQ ID NO:18、26, HC的34加上LC的SEQ ID NO:25、27、33(t)HC的SEQ ID NO:18、26、35加上LC的SEQ ID NO:20、30、33,(u) HC的SEQ ID NO:18、26、34和LC的SEQ ID NO:20、27、40,以及(v)HC的SEQ ID NO:18、26、34和SEQ ID NO:20、31 LC的第33条;其中所述抗体特异性结合Tie 2受体的Ang1和Ang2配体中的至少一个。

著录项

  • 公开/公告号ES2660381T3

    专利类型

  • 公开/公告日2018-03-22

    原文格式PDF

  • 申请/专利权人 AMGEN INC.;

    申请/专利号ES20130185473T

  • 申请日2009-02-20

  • 分类号C07K16/22;A61K39/395;A61P35;C07K14;C07K19;

  • 国家 ES

  • 入库时间 2022-08-21 12:48:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号